COX Nicox SA

Number of voting rights as of October 31, 2023

Number of voting rights as of October 31, 2023

Nicox SA 

Société anonyme with a registered capital of € 50,170,498 

Head Office: 

DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis  

R.C.S. GRASSE 403.942.642 

On November 2, 2023, 

MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS 

(Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l’AMF) 

 As of October 31, 2023 
Total number of shares composing the share capital 50,170,498 
Total number of voting rights 50,170,498 
Total number of voting rights, calculated based on the total number of shares, including the shares deprived of voting rights 50,170,498 

--------------- 

 

Phone: 00 

Fax : 99 

 

Attachment



EN
02/11/2023

Underlying

COXNicox SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nicox SA

 PRESS RELEASE
Free
COX NICOX SA

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting ...

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representativeJune 6, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, reminds its shareholders that the Ordinary and Extraordinary General Meeting will be held on Friday, June 27, 2025 at 2:30 p.m., at the Company’s headquarters locate...

16h / 59m 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire...

Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 juin 2025 et désignation d’un mandataire ad hoc Communiqué de presseNicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 juin 2025 et désignation d’un mandataire ad hoc 6 juin 2025 – publication à 7H30 Sophia Antipolis, FranceNicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, rappelle à ses actionnaires que l’assemblée générale ordinaire et extraordinaire, se tiendra le vendredi 27 juin 2025 à 14 heures 30, au siège ...

16h / 59m 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces up to €3 million in Milestone Payments from Kowa in 20...

Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Press Release Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in JapanMilestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025Extends Nicox’s cash runway until the end of 2025 May 27, 202...

May 27, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la p...

Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon Communiqué de presseNicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon Kowa, le partenaire exclusif de Nicox au Japon, a obtenu l’autorisation règlementaire de lancer des essais cliniques de Phase 3 sur NCX 470 pour le traitement de l’hypertension oculaire au Japon  Des paiements d’étapes pouvant atteindre ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
COX NICOX SA

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma ...

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial  Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety have already been demonstrated in the Phase 3 glauco...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch